Drug trial will record people's heart rhythm with wearable "patch" device.

24th March 2016

People on a trial for a new drug for hypertrophic cardiomyopathy are having their heart rhythms checked with a new wearable recording “patch”.

The research is assessing the effects of the drug eleclazine on exercise capacity and quality of life in people with hypertrophic cardiomyopathy (HCM).

Those taking part are to be given the new Zio patch, a disposable long-term monitor that remotely and wirelessly watches people’s heart rhythm. The small device sticks to the chest.

Pharmaceutical companies are keen to incorporate wearable devices for monitoring patients taking part in clinical trials.

Gilead Sciences, an American biopharmaceutical firm, started the 180 patient drug trial in February and will also use the study to test the suitability of the patch technology.  The device will be looking for various heart rhythm problems including non-sustained ventricular tachycardia and episodes of atrial fibrillation (AF).

Researchers say this will help them determine if the treatment improves symptoms such as AF in patients with symptomatic HCM.

“This is the first study of its kind for looking how to optimise treatment for HCM,” said a spokesman.